Data Insights

KT-253 by Kymera Therapeutics for Merkel Cell Carcinoma: Likelihood of Approval

KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Merkel Cell Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - KT-253 in Merkel Cell Carcinoma

Data Insights

KT-253 by Kymera Therapeutics for Adenoid Cystic Carcinoma (ACC): Likelihood of Approval

KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Adenoid Cystic Carcinoma (ACC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - KT-253 in Adenoid Cystic Carcinoma (ACC)

Data Insights

KT-253 by Kymera Therapeutics for Uveal Melanoma: Likelihood of Approval

KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Uveal Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - KT-253 in Uveal Melanoma

Data Insights

KT-253 by Kymera Therapeutics for Renal Cell Carcinoma: Likelihood of Approval

KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Renal Cell Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - KT-253 in Renal Cell Carcinoma

Data Insights

KT-253 by Kymera Therapeutics for Sarcomas: Likelihood of Approval

KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Sarcomas. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - KT-253 in Sarcomas

Data Insights

Risk adjusted net present value: What is the current valuation of Kymera Therapeutics's KT-253?

KT-253 is a small molecule commercialized by Kymera Therapeutics, with a leading Phase I program in Merkel Cell Carcinoma. According...

Net Present Value Model: Kymera Therapeutics Inc's KT-253